We’re excited to announce Keryx Biopharmaceuticals has merged with Akebia Therapeutics creating a fully integrated company focused on the development and commercialization of therapeutics for patients with kidney disease.

Learn about the merger Learn more about Akebia

Approximately 475,000 adults with chronic kidney disease require dialysis in the United States

Understanding Kidney Disease

More than half of all adults in the U.S. with chronic kidney disease are estimated to be iron deficient

Learn More About Iron Deficiency

We understand the consequences of kidney disease and are passionate about making a difference. Join our team!

Chronic Kidney Disease Affects

~30 Million Americans

Explore the Impact of Kidneys
Employee Spotlight

I wanted to join Keryx for the professionalism, the challenge and the fun! My favorite Keryx value is Collaboration. Collaboration is key for our company.”

Helen Zhang

Senior Manager, Quality Assurance

12/17 PP-AUR-US-0542

You are leaving www.keryx.com.

You are leaving www.keryx.com, a website of Keryx Biopharmaceuticals, Inc. Keryx does not review or control the content of non-Keryx websites, and this hyperlink does not constitute an endorsement by Keryx of the site’s content. Keryx’s privacy procedures do not apply to the owners of a non-Keryx website.